
Objective: This study aimed to identify major histocompatibility complex (MHC)-region genetic risk determinants beyond human leukocyte antigen (HLA)-B27 for radiographic axial spondyloarthritis (rad-axSpA) in Koreans by comparing patients with healthy controls (HC). Methods: We analyzed 692 patients with rad-axSpA and 5,000 HCs. After extracting the extended MHC region (chr6: 25,000,000~34,000,000), HLA imputation was performed using SNP2HLA with the Korean Reference Panel v1.0. Association analyses were performed for 4-digit classical HLA alleles in discovery and replication sets using logistic regression under an additive dosage model, adjusting for population structure with principal components (PC1~PC10) derived from non-MHC variants. Significance required p<5×10 –8 in discovery and p<0.05 with concordant direction in replication. Conditional analyses additionally adjusted for imputed HLA-B27 dosage. Results: In the unconditioned analysis, seven 4-digit HLA alleles reached genome-wide significance in the discovery set, with concordant, nominally significant associations (p<0.05) in the replication set; HLA-B*27:05 showed the strongest association. In HLA-B27–conditioned analyses, two 4-digit HLA alleles reached genome-wide significance in the discovery set, with concordant, nominally significant associations in the replication set: HLA-C*02:02 and HLA-C*08:02. Conclusion: In Koreans, HLA-B*27:05 was the predominant HLA-B27 subtype associated with rad-axSpA. We identified seven significant 4-digit HLA alleles in the unconditioned analysis and two additional 4-digit alleles after conditioning on HLA-B27, supporting MHC susceptibility beyond HLA-B27. Further studies are warranted to validate these findings and clarify their biological and clinical implications.
Objective: To examine the relationships between changes in the proportions of immune cell populations and clinical response at 2 weeks post-treatment with methotrexate (MTX), tumour necrosis factor (TNF) inhibitors, or abatacept, with treatment efficacy at week 12 in patients with rheumatoid arthritis (RA). Methods : Peripheral blood samples were collected from 30 patients with RA who received MTX (n=10), a TNF inhibitor+MTX (n=10), and abatacept+MTX (n=10) in this observational study. Of these, 25 patients completed the 12-week follow-up and were included in the efficacy and correlation analyses (MTX: n=9; TNF inhibitor+MTX: n=8; abatacept+MTX: n=8). Immune cell phenotypes were determined using 11-colour flow cytometry at baseline and 2 weeks after drug administration. Results : Baseline proportions and changes in several immune cell types at 2 weeks post treatment correlated with the efficacy of arthritis treatment at week 12. Specifically, a higher baseline proportion and a greater decrease at week 2 in class-switched memory B cells following MTX administration were significantly associated with treatment efficacy for arthritis, as were the same changes in activated Th1 cells following abatacept administration. Increases in effector memory CD8+ T cells were also significantly correlated with the efficacy of TNF inhibitor treatment in RA patients. Conclusion : This exploratory study identified a potential association between baseline or early changes in immune cell populations and subsequent clinical responses in RA.